CA-SYNACK
6.6.2019 17:02:17 CEST | Business Wire | Press release
Today, Synack, the most trusted crowdsourced security testing platform and top choice of major enterprises and governments, becomes the only crowdsourced penetration testing company to offer secure and managed workspaces with endpoint control. LaunchPoint+ extends Synack’s original LaunchPoint VPN offering by providing a managed workspace environment for crowdsourced testing of enterprise and government assets.
In the midst of calls for greater consumer privacy from the European Commission to Apple, and states like NY and CA introducing bold privacy bills, Synack is launching their new LaunchPoint+ product to help organizations meet today’s rising security standards. Just as Apple now provides privacy-as-a-service (PaaS) to accommodate consumer privacy demands in their latest iOS upgrade, Synack is providing additional privacy and data control to its customers.
As GDPR, HIPAA, PCI-DSS and ISO 27001 require increasingly stringent requirements for data privacy, Synack has developed a new offering to help meet, and in some cases exceed, what is required. In use cases that require extra care (such as where PII data is involved), consumers and regulators alike are increasingly demanding more attention for data privacy. A violation of GDPR could result in a fine of up to 4% of annual revenue, incentivizing organizations to protect the data in their care.
Many organizations, both governments and enterprises, are held to regulatory standards that demand heightened requirements around privacy. For others such as Apple, enforcement of privacy is a way to develop more trust with their customers and differentiate their brands. In a recent survey by SAS, 73% of consumers said their concerns over data privacy were increasing. Synack has responded by providing managed workspaces with endpoint controls to give these organizations the data protection and privacy environment during the testing period that they need.
As the leader of crowdsourced security, Synack has continuously brought to market new technology features that build, measure, and demonstrate trust between enterprises and their customers, and organizations and ethical hackers. Through innovations like the Attacker Resistance Score, Coverage Analytics, Trust Report, and Guardians of Trust Awards, Synack has put the trust and privacy of its customers first. LaunchPoint+ is another example of that commitment.
For Synack customers, the company’s new workspace will enable endpoint control, data privacy objectives, and improved trust between customers and researchers.
“We’ve set out to build trust between organizations and ethical hackers since our founding in 2013. We’re really excited to continue enhancing the Synack platform with technology feature updates like LaunchPoint+, because these are what give customers more control and make the crowdsourced testing model more trusted,” Synack CTO and co-founder Mark Kuhr said.
“The ability to have enhanced security controls directly applied to the attack workstation will help ensure data privacy and compliance requirements are met and consistently enforced,” says David Charlton, former Head of Penetration Testing at J.P. Morgan Chase & Co, and Synack’s Head of Product Strategy.
For Synack Red Team researchers, LaunchPoint+ will eradicate the need to manually connect to a VPN server and ensure a stable connection with reduced network latency. When asked for feedback, Synack Red Team researchers said they were “happy with the concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot.”
As more security teams move towards crowdsourced penetration testing, Synack leads the way in trust by offering features like LaunchPoint+ that ensure private, safe and controlled testing.
About Synack
Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190606005487/en/
Contact:
Ellie McCardwell press@synack.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
